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The Immunology of Inflammatory Bowel Disease 
Hugh L N. MacKechnie, M D ' 
Although several measurements of both cellular and hu-
moral immunity are altered in inflammatory bowel disease 
(IBD), no direct pathogenic role can be confirmed in either 
ulceradve colids (UC) or Crohn's disease (CD). No clear role 
has been shown for allergic, microbiological, or psycho-
genic factors, and no specific genetic susceptibility has been 
demonstrated. 
Several studies have shown some benefit from using immu-
nosuppressive drugs to treat inflammatory bowel disease, 
such as sulfasalazine to treat ulceradve colids and cortico-
steroids to treat Crohn's disease. Whether these benefits 
derive from the and-inflammatory acdvity ofthese drugs or 
from their immunological effects is uncertain. 
In the United States, the incidence of inflammatory bowel 
disease, e.g., Crohn's disease (CD) and ulcerative colitis 
(UC), is estimated at 500,000 to 2 million (1). The frequency 
and prevalence of Crohn's disease is increasing, while the 
incidence of ulcerative colitis appears to have stabilized. 
The etiology of both Crohn's disease and ulcerative colitis 
remains obscure. Several mechanisms have been proposed, 
including infectious processes by bacteria or viruses, im-
mune mechanisms, genetic factors, abnormalities of the 
lymphoid cell system and of the intestinal lymphatics, and 
psychogenic factors. 
Psychogenic factors appear to play a secondary rather than a 
primary role in both types of inflammatory bowel disease 
(IBD). Although significant emotional events may trigger an 
episode of ulcerative colitis, there is not enough objective 
evidence to substantiate a direct causal relationship, espe-
cially since medical and/or surgical treatment can suc-
cessfully resolve the problems associated with this disease. 
Emotional stresses are also implicated in the recurrence of 
Crohn's disease, although their direct role in its patho-
genesis is unlikely, based on current knowledge. 
Unfortunately, no experimental model exists for either 
Crohn's disease or ulcerative colitis. 
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Histology 
In ulcerative colitis, the inflammatory process primarily 
involvesthe colonic mucosa and submucosa, which consist 
of infiltrates of both lymphocytes and plasma cells and, to a 
lesser extent, eosinophils and polymorphonuclear cells (2). 
MAST cells and plasma cells are also increased, wfth an 
alteration in the ratio of IgG-to-lgA plasma cells from a 
normal ratio of 1/20 to an abnormal ratio of 4 /1 . C3 has been 
shown at the basement membrane of epithelial cells. Reac-
tive hyperplasia may be seen in regional lymph node cells. 
The earliest lesions in Crohn's disease, which is a full 
transmural inflammation ofthe colon, areaphthoid ulcera-
tions often located over lymphoid aggregates wfth subse-
quent lymphatic obstruction, lymphocytic infiltration, and 
edema. Although granulomatous tissue reaction can occur, 
30-40% of Crohn's patients may not have any detectable 
granuloma. 
Allergic Factors 
At present, no clear role has been found for allergic factors in 
inflammatory bowel disease. In one study, no significant 
difference in a personal or family history of atopic disease 
existed between 74 IBD patients (39 with ulcerative colitis, 
35 with Crohn's disease) and a control group. IgE levels, as 
well, did not differ. Patients wfth inflammatory bowel 
disease tended to have more positive prick tests to food, 
especially eggs, milk, and cereals, but the total number of 
skin tests did not significantly differ. These results likely 
reflect only increased absorption of food antigens. How-
ever, atopy is suggested by the finding of increased tissue 
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and peripheral eosinophilia and greater numbers of IgE 
plasma cells in the rectal mucosa of patients with proctitis. It 
has also been suggested that sodium cromoglycate, which is 
a MAST cell stabilizer, has a beneficial effect on inflamma-
tory bowel disease (3). 
Microbiological Factors 
In ulcerative col itis and Crohn's disease, gut bacterial counts 
are increased for both aerobic and anaerobic bacteria, 
which may contribute to the inflammatory reaction in the 
bowel. Bacterial possibilities include bacteriodes and E. 
coli. In Crohn's disease, the anaerobic Yersinia entero-
colitica has been isolated in some cases. 
In 1970, Mitchell and Rees (4) induced granulomas in mice 
by injecting their foot pads with intestinal tissue and mesen-
teric lymph node homogenates from Crohn's disease pa-
tients; however, the process took up to 500 days. A 
transmissible agent, which appears to be a picornavirus, has 
been found in Crohn's disease patients. It is heat stable, can 
withstand freezing upto - 7 0 ° and is sensitive to autoclav-
ing. A separate agent for ulcerative colitis has also been 
found. 
Parent and Mitchell (5) have recently shown a cell wall 
defective, pseudomonas-like organism in eight of eight 
patientswithCrohn's disease by culturingbiopsy material in 
hypertonic media before filtration. However, they could not 
demonstrate it in nine patients with ulcerative colitis or in 20 
control patients who did not have inflammatory bowel 
disease (colon carcinoma, colon polyps, endometriosis, 
vascular malformation, pancreatic carcinoma). Few clinical 
diseases have been shown to be due to cell wall defective 
bacteria, and parent organisms could not be shown in the 
tissues studied (5). Cell wall defective bacteria may arise via 
antibody plus complement, or by antibiotic exposure, and 
generally revert to parental form in orderto produce disease. 
They evade cell wall directed bacteriocidal antibiotics 
(penicillins, cephalosporins); they may even reside within 
red blood cells and hence escape lymphocyte action. They 
may also persist in po lymorphonuc lear cells or mac-
rophages or revert to their parent forms. 
Cell wall defective bacteria, with their slower replicating 
rate, present a less acute antigenic challenge that results in 
more prolonged exposure to immunogenic cells and higher 
antibody levels. If immune complexes were formed in slight 
antibody excess or at equivalence (equal antigen and anti-
body amounts), then granulomatous inflammation, as seen 
in Crohn's disease, would be favored (6). The neutrophil 
defect seen in some patients (7-9) may contribute to gran-
uloma formation by producing a situation analogous to the 
chronic granulomatous disease of childhood. 
Kagnoff (10) in an editorial pointed out that Parent and 
Mitchell performed their study without a screened control 
group and without using a neomycin-erythromycin bowel 
preparation before surgery. The high levels of serum 
lysozyme found in Crohn's patients may also produce cell 
wall variants. Antibiotics such as tetracyline, which are 
effective against cell wall defective bacteria, are not consist-
ently effective in managing inflammatory bowel disease 
(10). 
Genetic Factors 
In 15-20% of patients with inflamatory bowel disease, 
genetic factors are suggestive (1). In some cases, the disease 
has occurred in three or more members ofthe same family 
over three generations, ft also occurs in monozygotic twins 
with an increased concordance ratio. A strong genetic 
predisposition also exists in the patients who have both 
inflammatory bowel disease and ankylosing spondylitis. 
The genetic factor may be a polygenic type of inheritance 
that primes a susceptible person to develop inflammatory 
bowel disease given the appropriate environmental, emo-
tional, or infectious stresses. No specific HLA types have 
been associated with inflammatory bowel disease other 
than the HLA-B27 of ankylosing spondylitis. The occur-
rence of inflammatory bowel disease in families, however, 
may reflect only common antigenic exposure. 
In a recent study (11), lymphocytotoxic antibodies were 
detected in 27 of 53 patients (51%) versus 11 of 53 (11%) 
controls and in 23 of 53 (43%) patient spouses versus 3 of 53 
control spouses (6%). Lymphocytotoxic antibodies are 
formed in response to and are markers of the presence of an 
infectious agent either through sharing of antigenic determi-
nants with surface membrane determinants on lymphocytes 
or through interference by the agent with the normal state of 
tolerance to such determinants. These antibodies are cold 
reactive with maximum activity at 15°C. They are non-HLA-
dependent, reacting predominantly to T cells of the IgG or 
IgM class. They are seen in acute viral infections such as 
infectious mononucleosis and systemic lupus erythe-
matosus. There is no relationship between their titer and 
disease activity, duration, extent, or treatment mode. 
In a study from Israel (12), 53.5 % of 60 Jewish patients with 
ulcerative colitis were found to be HLA-Bw35 positive 
versus 30.6% of controls. There was also a suggestion that 
HLA-AW 24 was associated with an earlier onset and more 
severe disease. However, Crohn's disease patients did not 
show any significant correlations in terms of HLA antigen 
differences when compared to a control population. The 
same study showed that the frequency of HLA-Bw35 in-
creased in patients with myasthenia gravis, rheumatic fever, 
atopic dermatitis, subacute thyroiditis, Grave's disease, and 
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necrotizing venulitis (12). This finding suggests a possible 
association between specific immune response genes and 
HL-A antigens that may be more evident in this Israeli 
population than in the U.S. population. Genetic factors in 
Crohn's disease have also recently been shown in studies of 
kindreds with this disease (13). 
Immunological Mechanisms in 
Inflammatory Bowel Disease 
In 1964 Palmer and Kirsner (14) first proposed a possible 
role for immune mechanisms in producing the lesions of 
inflammatory bowel disease. However, experimental at-
tempts to reproduce these lesions by immune mechanisms 
have so far failed. There is no good animal model. The 
finding of colonic ulcerations by colonoscopy in patients 
with systemic lupus erythematosus is of interest, though, as 
they are similar to those seen in the early stages of Crohn's 
disease. 
Humoral immunity 
No specific immunoglobulin abnormalities have been 
found in either ulcerative colitis or Crohn's disease. The 
normal ratio (10/1/1) of IgA/lgG/lgM-bearing cells in the 
lamina propria is altered in inflammatory bowel disease, 
and plasma cells are found in the deeper layers of the 
bowel wall where they are not normally found. It has been 
reported that IgG levels are higher in ulcerative colitis and 
IgM levels are lower in Crohn's disease; however, in a 
study of 93 patients with ulcerative colitis (65 patients with 
Crohn's disease and 53 hospitalized control patients), the 
mean level of all immunoglobulins was significantly ele-
vated, while only the IgM level was significantly raised in 
Crohn's disease (15). 
In one study of Crohn's disease (16), granulomas were seen 
predominantly in the medullary cords (a B cell area of 
lymph nodes) and only occasionally in the paracortical 
areas (T cell area). Within the granulomas, though, mac-
rophages were seen. This study suggests that the infiltrate in 
Crohn's disease is composed primarily of B cells with some 
T cell modulation. 
Chronic gut inflammation may stimulate antibody forma-
tion against antigens in the gut lumen resulting in the 
production of antibodies to both bacterial and dietary 
antigens. This local antibody production may spill over into 
the systemic circulation. Inflammation may increase the 
permeability of the mucosa to antigens and contribute to 
the hypergammaglobulinemia, especially with colon in-
volvement, as bacterial counts are significantly higher. 
Engstrom, et al (17) have reported on one family with 
secretory piece deficiency (and hence no secretory IgA) 
with inflammatory bowel disease. In this instance, the lack 
of IgA might increase susceptibility to infection or permit 
bacterial antigens to invade the mucosa. 
An antigen to human colon has also been isolated from the 
colon and cecum of germ-free rats that is gastrointestinal-
specific but not colon-specific. Antibodies against this 
antigen cross-react with E. coli 014 lipopolysaccharide 
antigens, not only in patients with ulcerative colitis or 
Crohn's disease, but also in relatives of IBD patients who 
do not have the disease. However, these colon antibodies 
do not correlate with duration, extent, severity ofthe bowel 
disease, age, or the sex of the patient. They cannot be 
identified in involved tissues, they are not cytotoxic to fetal 
colonic epithelial cells in culture (even with added com-
plement), and they can persist after colectomy for two to 
ten years. These antibodies may represent only the in-
creased bacterial absorption that follows mucosal inflam-
mation, as the same antibodies can be produced after 
salmonella and shigella colitis (18). Moreover, when Hed-
dle and Shearman compared antibody levels to E. coli 014 
in patients with ulcerative colitis and in a control popula-
tion, no increase was found (18). Consequently, it is likely 
that these antibodies have a secondary role. 
In one third of patients with ulcerative colitis and Crohn's 
disease, one can demonstrate circulating immune com-
plexes by the technique of inhibition of antibody-depen-
dent cellular cytotoxicity (19). Other studies that used the 
Clq precipitation technique showed that immune com-
plexes were present in up to 85% of patients with active 
disease. However, this method can give false positive 
results through its binding with single-stranded DNA or 
endotoxin (19). 
Although both IgG and IgM can be produced locally from 
mucosal plasma cells, the nature of the antigen remains 
unknown. IgG, C3, and Clq have been shown by means of 
immunofluorescence on the surface epithelial cells of the 
colon at basement membrane level. In one animal study 
(20), rabbits with formalin-induced, rectal mucosal damage 
were given human serum albumin/anti-human serum al-
bumin intravenously. The result was a form of colitis histo-
logically similar to human ulcerative colitis, including the 
presence of crypt abscesses. Hodgson (20) suggests that if 
acute colitis is severe enough to allow gut-associated anti-
gens to be adequately absorbed, then the patient's hyper-
sensitivity to colonic bacteria (possibly enhanced by a 
genetically programmed host) could allow the disease to 
become chronic. 
Levels of immune complexes in Crohn's disease also ap-
pear to correlate with disease activity and extraintestinal 
features. According to Lawley, et al (21), they are more 
common in patients with colonic involvement and disap-
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pear after the diseased bowel has been resected. These 
investigators found no correlation between antibody levels 
to E. coli and the degree of local inflammation in efther 
disease (21). Patients with positive immune complexes 
have also shown increased eosinophilia in both colonic 
mucosa and mucus (22). 
Cellular immunity 
Delayed hypersensitivity skin tests, in general, have the 
same pattern (either hypersensitive or anergic) in both 
normal individuals and in patients with inflammatory 
bowel disease. Up to 70% of Crohn's disease patients are 
anergic to dinitrochlorobenzene (DNCB) versus 5% of 
controls, and 50% are anergic to other skin test antigens 
such as purified protein derivative (PPD) and streptokinase-
streptodornase (SK/SD). In a recent study (23), only two of 
10 patients with Crohn's disease had one or more positive 
hypersensitivity skin tests at 43 hours (<10 mm induration). 
The eight who did not respond were given 1200 mg of the 
antihistamine cimetidine in divided daily doses and then 
were retested one month later. At that time, seven of the 
eight had one or more positive tests (especially to SK/SD), 
although no clinical changes were evident (23). ft is known 
that histamine by means of negative feedback via H2 
receptors on lymphocytes elevates c'AMP levels and sup-
presses lymphocyte funct ion. If the H2 ant ihistamine 
cimetidine blocked this action, then increased delayed 
hypersensitivity would be seen (23). Whether a month is 
long enough to assess an effect on clinical activity is not 
known but may be worth further study. 
T cell subgroups (helper cells, suppressor K cells) are in 
normal proportions in ulcerative colitis, although their total 
numbers may be reduced, presumably from their loss into 
the gut. Crohn's patients may have both decreased num-
bers and proportions o f T cells either from enteric loss or 
sequestration within the deeper layers of the bowel wall 
(24). The T cell levels, however, return to normal when 
disease remits. Other studies show that cell-mediated im-
munity is normal in the early stages of Crohn's disease and 
declines only with long-standing disease (24). 
Mitogenic stimulation with PHA (phytohemagglutinin) is 
normal in ulcerative colitis, although it has been reported 
as reduced in Crohn's disease patients (25), and in some 
cases it may persist at a low level in spite of medical 
therapy or surgery to eliminate the diseased bowel. Al-
though this suggests a primary defect in cell-mediated 
immunity in Crohn's disease, there is no correlation with 
disease activity or duration of illness (25). 
In the early stages of Crohn's disease, the mixed lympho-
cyte culture responsiveness of peripheral blood lympho-
cytes is normal, yet some decreased function has been 
shown in long-standing disease (26). Lymphocytes also 
have a cytotoxic effect on colonic epithelial cells that is 
found only in inflammatory bowel disease, although there 
is no cytotoxicity to gastric and ileal cells. This effect is 
rapid, tissue-specific, and does not require complement; it 
can also be produced by cell-free filtrates. It disappears 
within 10 days after colectomy (ulcerative colitis) or resec-
tion (Crohn's disease), but returns if Crohn's disease recurs. 
One can block this cytotoxicity by preincubation with anti-
T cell anti-sera or by preincubation with E. coli 0119 B14 
lipopolysaccharide. It is transferable by the patient's sera 
via IgM antibody or via sensitized T cells (K cells) which are 
armed by immune complexes with free antibody (antibody 
excess). 
Hodgson, et al (27) looked at the conconavalin-A-stimu-
lated suppressor cell activity of peripheral mononuclear 
cells in 11 patients with ulcerative colitis or Crohn's dis-
ease. In both healthy and hospitalized controls, the al-
logeneic lymphocyte-induced blast transformation was 
suppressed by 27.4%, but in the patients with inflammatory 
bowel disease it was suppressed by 9.2% (P<0.005). Five 
patients showed a helper effect The degree of suppression 
correlated wfth disease activity: the more severe the dis-
ease, the higher the rate of suppression. One patient with 
toxic megacolon who was followed serially had a disease 
remission before normal suppressor function returned. This 
suggests that the loss of suppressor function might allow 
inf lammat ion to persist by fa i l ing to contro l immune 
responsiveness. 
Measuring cellular immunity in IBD patients presents many 
technical problems. Paramount among them is the use of 
crude antigens, since the specific antigens are not known. 
Timing is also important in terms of disease activity, dura-
tion, and treatment, as are considerations such as a defi-
c iency of fol ic acid, wh ich is required for blast cel l 
transformation (27). 
Complement levels 
In one study of 93 patients with ulcerative colitis, 66 with 
Crohn's disease, 20 healthy controls, and 31 hospitalized 
patient controls (ulcer, disc disease), the levels of C3, C4, 
and Clq factor B (C3 proactivator) were measured (29). In 
the IBD patients, levels of all complements except C4 were 
higher. In general, the more extensive the colonic disease, 
the higher were the C3 and factor B levels. These were not 
affected by steroids or by skin, joint, or eye complications. 
Patients with liver disease had significantly lower C4 levels, 
while those patients with immune complexes had higher 
levels of C3 and factor B. Since neither C3c nor C3d was 
found, the pattern of rise of these proteins is that of acute 
phase reactants (29). In the immune complexes of ulcera-
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tive colitis and Crohn's disease patients, the C3 conversion 
products increased, as did the C3 fractional catabolic rate. 
Some investigators have also shown alternate pathway 
activation (low properdin levels). Lake, et al (30) performed 
a prospective study of 32 patients with inflammatory bowel 
disease at the time of diagnosis and before therapy was 
started. Although classical pathway components indicated 
normal levels and function, patients with extraintestinal 
manifestations of inflammatory bowel disease had low 
levels of properdin and properdin convertase, while pa-
tients whose disease was confined to the colon had normal 
levels. Although these findings may reflect only inflamma-
tory activity, IgA and/or IgE complexes may play a role. 
Skin Reactivity and Phagocytic 
Function of Neutrophils 
In general, delayed hypersensitivity skin tests of IBD patients 
cannot be used to predict the clinical course of the disease 
reliably (31). In one study (31), 43 patients with Crohn's 
disease, 20 with ulcerative colitis, and 54 controls with 
minor skin diseases or urticaria were tested intradermally 
with various bacterial antigens. Crohn's disease patients asa 
group tended to have more positive reactions but not to any 
specific antigen. In another study (32), the phagocytic index 
for yeast particles of Crohn's disease patients versus controls 
was low, especially if the ileum was involved, whereas the 
phagocytic index of ulcerative colitis patients was the same 
as for the control group. 
The nitroblue tetrazolium test has produced conflicting 
results. In one study (7), the results were normal for both 
Crohn's disease and ulcerative colitis patients, whereas in 
another study the test scores were low (8). However, these 
low scores were felt to be related to the presenceof immune 
complexes in these patients, since immune complexes have 
been shown to elevate low test scores by neutrophils. In the 
former study (7), the skin window technique was used on 
Crohn's disease patients to demonstrate defective neu-
trophil migration, although in vitro tests (chemotaxis assays) 
showed that polymorphonuclear function was normal. 
Monocyte accumulation, though, was normal at 24 hours in 
the assays. This abnormal acute inflammatory response 
could lead to antigen persistence and predispose to chronic 
inflammation (6). 
The Immunological Role of the 
Gastrointestinal Tract 
The numbers ofT lymphocytes present in the bowel wall are 
increased in inflammatory bowel disease, especially in 
Crohn's disease. The increase occurs primarily in the sub-
mucosa and deeper layers of the bowel wall and possibly 
reflects a chronic immune reaction with the diseased gut in 
response to a primary antigenic challenge to the bowel that 
may be bacterial (1). Intraepithel ial lymphocytes 
ftheliolymphocytes) are also more numerous in inflamma-
tory bowel disease than in the normal bowel. Evidence 
suggests that these lymphocytes may be abnormal both 
structurally and functionally, as they respond better to PHA 
than to concanavalin A, which is the reverse of the normal 
response. 
Also, the amount of secretory IgA appears to be decreased in 
the rectal epithelium of involved rectal mucosa in ulcerative 
proctitis and in 40% of proximal, normal-appearing sigmoid 
colon mucosa (33). This decrease suggests a local immune 
defect that may increase antigen penetration and vul-
nerability. Rectal biopsies of patients with both ulcerative 
colitis and Crohn's disease demonstrate increased numbers 
of IgE plasma cells. The role ofthese cells and the increased 
numbers of MAST cells in the colonic tissue of IBD patients 
suggests an immediate hypersensitivity response. Clinical 
trials of cromolyn sodium, as discussed below, have been 
held to study this response (48). 
In summary, patients with inflammatory bowel disease have 
decreased numbers of T cells (and decreased PHA and 
antigen stimulation) as well as increased numbers of B cells 
(25-34). The significance of the pathophysiological role of 
decreased suppressor cell activity is unclear at the present 
time (27). Further uncertainty also arises because none ofthe 
above laboratory variables has any direct correlation with 
disease site, duration, activity, therapy, or malnutrition. An 
exception are those patients with high levels of immune 
complexes (34). 
Whether these changes are primary (hence causal) or sec-
ondary (epiphenomenon) is not clear at the present time. 
Perhaps the initiating event is an infectious process that 
causes mucosal damage and loss of suppressor T cells with 
increased mucosal absorption of bacterial antigens. In this 
way, inflammation could persist and the disease would 
become chronic. The level of penetration of these antigens 
could determine if ulcerative colitis at the mucosal level or 
Crohn's disease at the level of the submucosa and deeper 
would occur. The alternate complement pathway may also 
be activated by endotoxin from gram-negative bacteria (35). 
Therapeutic Considerations 
Ulcerative colitis 
Sulfasalazine has been used successfully for many years in 
ulcerative colitis. The drug consists of 5-aminosalicylic acid 
and sulfapyridine linked with an azo bond. Reduction via 
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cleavage at the azo linkage occurs in the 70% ofthe drug 
that reaches the colon, and the absorbed sulfapyridine is 
metabolized and excreted. Although only minimal amounts 
ofthe 5-aminosalicylic acid are absorbed, it has been shown 
to be helpful clinically when applied locally. Several effects 
on polymorphonuclear function can be demonstrated, such 
as decreased migration, superoxide production, and my-
eloperoxidase-mediated iodination and cytotoxicity. Inhibi-
tion of fecal prostaglandin levels probably reflects only 
reduced inflammation and granulocyte accumulation that 
does not occur via a direct synthetic inhibitory effect (24). 
Bean in 1962 (36) first reported the beneficial effect fromthe 
useof 6MP, andthe University of Chicago in 1966 reported 
that eight of 10 cases improved with azathioprine, although 
the dose was high (4-6 mg/kg/day for 2-3 weeks and then 
2-3 mg/kg/day) (37). However, it was not until 1972 that the 
first controlled trial was published that showed that 11 of 20 
patientson azathioprine were free of symptoms forone year 
versus 5 of 20 patients on a placebo (38). Although the long-
term benefit was less clear (39), many studies showed some 
benefit especially in allowing a reduction in the steroid 
dosage. 
In all, many drugs have been tried, including chlorambucil 
and busulfan as well as nitrogen mustard (mechorethamine), 
but there appears little justification for their use since the 
disease can be cured by colectomy. 
Crohn's disease 
In Crohn's disease, drug therapy can be better justified since 
the disease has no known cure, but even here no treatment 
has been shown to be helpful in reducing postoperative 
recurrences, which are as high as 30-60% (40). 
The first trial of azathioprine was reported in 1969 (41), with 
six treated patients showing improvement over a six-month 
follow-up period. In the uncontrolled trials that followed, 
steroid requirements decreased and fistulae were healed. 
Between 1974 and 1978, there were seven randomized, 
controlled trials using 6MPor azathioprine (42). One study 
by Willoughby (43) of 22 patients in a 24-week, double-
blind trial showed that 10 of 11 patients on azathioprine 
remained in remission for 24 weeks versus 8 of 11 placebo 
patients who relapsed. 
A time period of at least four months may be needed to show 
the benefit, as other studies (44-45) have suggested that a 
peak response occurs only after three to nine months. A 
recenttrial showed that 32% of patients did not benefit from 
6MP and steroids for at least three months and that 19% 
benefited after four months. 
In another study (46), metronidazole, which is antibacterial 
to some anerobes, used in a dose of 20-40 mg/kg/day 
produced good clinical improvement in 13 of 17 treated 
patients. Other studies could not confirm these results, 
although Crohn's disease may possibly have improved 
through the antibacterial action (47) of the drug. 
Cromolyn sodium has also been used in a double-blind, 
crossover trial in doses of upto 2 gm perday per month (48). 
Twelve patients were significantly improved in their sense of 
well-being, sigmoidoscopic appearance, histology, and 
total eosinophil count reduction over a six-month trial 
period (48). Heatley, et al (49) reported that in their study 
there was a good response to combined oral and topical 
cromolyn in chronic proctitis, especially where the total 
eosinophi l count in the lamina propria was high. 
Willoughby, et al (50) compared disodium cromoglycate to 
salazopyrine in maintaining remission in 120 patients with 
ulcerative colitis. On cromoloyn alone there was a 44% 
relapse rate fthe same as placebo) versus a 12% relapse rate 
on salazopyrine. They could not demonstrate a good prog-
nostic effect from the number of lamina propria eosinophils 
and felt that Heatley's good results reflected the use of 
cromolyn as a topical retention enema (50). 
Three trials of BCG with various techniques have been 
published. In an uncontrolled trial (51), Geffroy suggested 
improvement in Crohn's disease when BCG was admin-
istered by scarification, while Dupuy's study failed to show 
any benefit (52). Using oral BCG, Rahban in nine cases (53) 
failed to show any changes in x-ray, clinical parameters, or 
laboratory values. Although the five patients who were 
initially DNCB-negative became positive, no improvement 
was seen. 
A double-blind, controlled trial of transfer factor from 
"healthy" relatives of patients with Crohn's disease failed to 
produce any benefit, and no changes in T or B cell function 
were seen, although there was a trend to converting the 
negative delayed hypersensitivity skin tests to positive (54). 
Although treatment of Crohn's disease with drugs like the 
corticosteroids helps in controlling acute relapses, no agent 
has as yet been shown that wil l alter the natural history and 
prevent relapses, ft would seem that this goal must awaft a 
more complete understanding ofthe specific pathophysiol-
ogy involved in inflammatory bowel disease. 
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